Pandit Lekha
Professor of Neurology, Director of Center for Advanced Neurological Research, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangalore, Karnataka, India.
Ann Indian Acad Neurol. 2019 Jul-Sep;22(3):261-263. doi: 10.4103/aian.AIAN_159_19.
A combined endpoint measure to define no evidence of disease activity (NEDA) is becoming increasingly appealing in the treatment of multiple sclerosis (MS). Initial efforts using a 3 parameter NEDA monitored disease activity using clinical and MRI lesion data. Later refinements, introduced more recently, include brain atrophy measurement and cognitive function analysis in defining NEDA-4. Using these stringent criteria clearly differentiated the usefulness of different disease modifying agents (DMDs) in achieving and sustaining NEDA over time. This in turn has changed attitudes and strategies in management of MS.
一种用于定义无疾病活动证据（NEDA）的综合终点指标在多发性硬化症（MS）治疗中越来越具有吸引力。最初使用三参数NEDA的研究通过临床和MRI病变数据监测疾病活动。最近引入的后续改进包括在定义NEDA-4时纳入脑萎缩测量和认知功能分析。使用这些严格标准能够清晰区分不同疾病修正药物（DMDs）在随时间实现并维持NEDA方面的效用。这反过来改变了MS管理中的态度和策略。
